RenovoRx to Participate March 2022 Investor Conferences

Los Altos, CA, March 10, 2022 – RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced its leadership’s participation in two upcoming Investor Conferences this month.

ROTH Capital Partners 34th Annual Conference

Format and Dates: In person, March 13-15, 2022
Location: The Ritz Carlton Laguna Niguel Hotel, Dana Point, CA
Presenters and Presentation Date/Time: Shaun Bagai, CEO, to present on Monday, March 14th at 1:30 p.m. PT
Webcast: https://wsw.com/webcast/roth43/rnxt/1869488
Register: Visit the event website

Maxim Virtual Growth Conference

Format and Dates: Virtual, March 28-30, 2022
Presenters and Presentation Date/Time: Shaun Bagai, CEO, to present on-demand
Webcast: https://m-vest.com/events/2022-virtual-growth-conference
Register: Visit the event website

Maxim Growth Conference Panel on Pancreatic Cancer

Format and Date: Virtual, Monday March 28, 12:00 – 1:00 pm ET
Presenter: Shaun Bagai, CEO, to participate with other industry leaders on pancreatic cancer panel.
Webcast: A link to this panel will be posted to the RenovoRx Website Events page when it becomes available.

RenovoRx leadership will be available during the events for one-on-one meetings with the investment community. To schedule a meeting please reach out to your respective conference representative or by emailing KCSA Strategic Communications: RenovoRx@KCSA.com.

About RenovoRx, Inc.

RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. RenovoRx’s lead product candidate, RenovoGemTM, is a combination of gemcitabine and our patented delivery system, RenovoCath®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC).  RenovoGem is currently being studied in the Phase 3 TIGeR-PaC trial for the treatment of LAPC.

RenovoRx’s patent portfolio includes seven U.S. patents for its technology. RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer.

RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards – Life Sciences Edition 2020 for its RenovoTAMP technology.

Learn more by visiting the RenovoRx website or following us on FacebookLinkedIn and Twitter.

Company Contact:

RenovoRx, Inc.
Shaun R. Bagai, CEO
Christopher J. Lehman, CFO

Investor Contact:

KCSA Strategic Communications
Valter Pinto or Jack Perkins
T: 212-896-1254
RenovoRx@kcsa.com

Media Contact:

Knight Marketing Communications, Ltd.
Kevin Knight
T: 206-451-4823
kknightpr@gmail.com

Previous Post
Shaun Bagai Discusses the RenovoRx Revolution
Next Post
RenovoRx Reports Full Year 2021 Financial Results
Menu